Pipeline

Cardiac Muscle Contractility

ProductPreclinicalPhase IPhase IIPhase IIIStatus
   
High Risk Heart Failure:
    
 
Safety and Efficacy (iv)
   
Phase IIb initiated in 2Q 2011
Stable Heart Failure:
    
 
Safety and Tolerability (iv)
   
Phase IIa completed in 2009
Ischemic Cardiomyopathy (iv/oral)
   
Phase IIa completed in 2008
Healthy Volunteers:
    
 
Drug/Drug Interaction (oral)
   
Phase I completed in 2008
Single-Dose to Multi-Dose (oral)
   
Phase I completed in 2008
Oral Modified Release (oral)
   
Phase I completed in 2008
Safety and Tolerability (iv)
   
Phase I completed in 2006
Bioavailability (iv/oral)
   
Phase I completed in 2006
    
 

Skeletal Muscle Contractility

ProductPreclinicalPhase IPhase IIPhase IIIStatus
   
ALS (single dose)
   
Phase IIa EOE completed in Q4 2010
ALS (multi-dose) without riluzole
   
Phase II completed in Q4 2011
ALS (multi-dose) with riluzole
   
Phase II initiated in Q4 2011
ALS (dose titration)
   
Phase II initiated in Q4 2011
Claudication
   
Phase IIa EOE completed in Q2 2011
Myasthenia Gravis
   
Phase IIa EOE initiated in Q1 2011
Drug-Drug Interaction and Food Effect
   
Phase I completed in 3Q 2011
      
   
Preclinical Development
   
IND-enabling Studies Ongoing

Smooth Muscle Contractility

ProductPreclinicalPhase IPhase IIPhase IIIStatus
   
Preclinical Development
   
Ongoing

Oncology

ProductPreclinicalPhase IPhase IIPhase IIIStatus
   
Breast Cancer
   
Data presented at ASCO 2009
      
   
Hodgkin/Non-Hodgkin Lymphoma
   
Data presented at ASH 2010
      
   
Advanced Solid Tumors
   
Data presented at ASCO 2010

Current status as of 12/11

[1] Partnered with Amgen

Cytokinetics Program Status Program Status
Cytokinetics Completed Clinical Trial Completed Activity
Cytokinetics Ongoing Clinical Trial Ongoing Activity
Cytokinetics Program Status Planned Activity